gliclazide has been researched along with Atherogenesis in 2 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karami, Z | 1 |
| Mehrzad, J | 1 |
| Akrami, M | 1 |
| Hosseinkhani, S | 1 |
| Jahan, H | 1 |
| Choudhary, MI | 1 |
2 other studies available for gliclazide and Atherogenesis
| Article | Year |
|---|---|
Anti-inflammation-based treatment of atherosclerosis using Gliclazide-loaded biomimetic nanoghosts.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Biomimetics; Gliclazide; Lagomorpha; Plaque, Ath | 2023 |
Gliclazide alters macrophages polarization state in diabetic atherosclerosis in vitro via blocking AGE-RAGE/TLR4-reactive oxygen species-activated NF-kβ nexus.
Topics: Animals; Antigens, Surface; Atherosclerosis; Cell Survival; Cytokines; Diabetes Complications; Diabe | 2021 |